Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
- Shibata, Stephen I.
- Chung, Vincent
- Synold, Timothy W.
- Longmate, Jeffrey A.
- Suttle, A. Benjamin
- Ottesen, Lone H.
- Lenz, Heinz Josef
- Kummar, Shivaani
- Harvey, R. Donald
- Hamilton, Anne L.
- O'Neil, Bert H.
- Sarantopoulos, John
- LoRusso, Patricia
- Rudek, Michelle A.
- Dowlati, Afshin
- Mulkerin, Daniel L.
- Belani Leena Gandhi, Chandra P.
- Lau, S. Cecilia
- Ivy, S. Percy
- Newman, Edward M.
Publication date
January 2013
DOIAbstract
Pazopanib is a potent, multi-targeted receptor tyrosine kinase inhibitor; however, there is limited information regarding the effects of liver function on pazopanib metabolism and pharmacokinetics (PK). The objective of this study was to establish the maximum tolerated dose (MTD) and PK profile of pazopanib in patients with varying degrees of hepatic dysfunction
Add to ORKG